Alkermes (ALKS) Competitors $30.79 -0.20 (-0.65%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALKS vs. ABEO, MEDP, OMCL, AMN, UTHR, INCY, NBIX, EXEL, BMRN, and IONSShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector. Alkermes vs. Its Competitors Abeona Therapeutics Medpace Omnicell AMN Healthcare Services United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Ionis Pharmaceuticals Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations. Is ABEO or ALKS more profitable? Alkermes has a net margin of 23.15% compared to Abeona Therapeutics' net margin of 0.00%. Abeona Therapeutics' return on equity of 89.05% beat Alkermes' return on equity.Company Net Margins Return on Equity Return on Assets Abeona TherapeuticsN/A 89.05% 45.64% Alkermes 23.15%24.86%17.14% Do insiders and institutionals have more ownership in ABEO or ALKS? 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor ABEO or ALKS? In the previous week, Abeona Therapeutics had 5 more articles in the media than Alkermes. MarketBeat recorded 10 mentions for Abeona Therapeutics and 5 mentions for Alkermes. Abeona Therapeutics' average media sentiment score of 0.20 beat Alkermes' score of -0.10 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, ABEO or ALKS? Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbeona Therapeutics$400K671.11-$63.73M$0.707.48Alkermes$1.56B3.26$367.07M$2.0814.80 Do analysts rate ABEO or ALKS? Abeona Therapeutics currently has a consensus price target of $19.50, indicating a potential upside of 272.49%. Alkermes has a consensus price target of $42.00, indicating a potential upside of 36.41%. Given Abeona Therapeutics' higher possible upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Alkermes 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.93 Which has more risk and volatility, ABEO or ALKS? Abeona Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. SummaryAlkermes beats Abeona Therapeutics on 9 of the 17 factors compared between the two stocks. Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.08B$3.31B$6.11B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio14.8021.5485.7226.89Price / Sales3.26414.18580.63183.63Price / Cash11.7246.3226.3031.10Price / Book3.4010.0313.236.68Net Income$367.07M-$52.22M$3.30B$276.44M7 Day Performance2.63%5.50%4.85%3.12%1 Month Performance2.84%11.70%8.50%10.19%1 Year Performance10.80%25.44%87.78%40.24% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes4.4662 of 5 stars$30.79-0.6%$42.00+36.4%+7.0%$5.08B$1.56B14.801,800ABEOAbeona Therapeutics4.4218 of 5 stars$5.33-2.0%$19.50+265.9%-17.3%$273.32M$3.50M7.6190MEDPMedpace4.2519 of 5 stars$500.76+0.8%$422.27-15.7%+54.6%$14.07B$2.11B37.235,900OMCLOmnicell3.9957 of 5 stars$30.34-1.2%$46.71+54.0%-28.0%$1.39B$1.11B60.683,670News CoveragePositive NewsAMNAMN Healthcare Services4.2962 of 5 stars$18.51-1.9%$23.25+25.6%-48.3%$709.38M$2.98B-2.382,968UTHRUnited Therapeutics4.3545 of 5 stars$424.31-1.9%$449.57+6.0%+27.4%$19.14B$2.88B16.561,305Insider TradeINCYIncyte4.5188 of 5 stars$83.89+1.4%$83.67-0.3%+29.2%$16.38B$4.24B19.072,617Positive NewsNBIXNeurocrine Biosciences4.7894 of 5 stars$140.27-1.2%$161.89+15.4%+22.3%$13.91B$2.36B41.501,800EXELExelixis4.8499 of 5 stars$40.57+3.9%$44.42+9.5%+50.1%$10.92B$2.17B19.501,147Positive NewsBMRNBioMarin Pharmaceutical4.9536 of 5 stars$54.02+0.3%$92.60+71.4%-20.0%$10.37B$2.85B16.033,040Positive NewsIONSIonis Pharmaceuticals3.4388 of 5 stars$64.15+0.1%$73.88+15.2%+82.1%$10.22B$705M-34.861,069Analyst Forecast Related Companies and Tools Related Companies Abeona Therapeutics Alternatives Medpace Alternatives Omnicell Alternatives AMN Healthcare Services Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Ionis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALKS) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
